Icotrokinra: The Pill That Acts Like a Shot

A Pill That Clears Skin Like a Shot

For twenty years, the deal in moderate-to-severe psoriasis has been simple and frustrating: if you want your skin truly clear, you inject. The biologics that target interleukin-23 — Skyrizi, Tremfya — produce results the old pills could only dream of, but they come as needles, cold storage, and prior-authorization paperwork. The oral options, meanwhile, were the consolation prize: real, but visibly weaker.

That bargain just changed. On March 18, 2026, the FDA approved icotrokinra — brand name Icotyde — the first oral drug that blocks the interleukin-23 receptor.³ It's a once-daily pill, and in its trials it cleared skin at rates that genuinely crowd the injectable IL-23 class. At AAD 2026 it was the headline launch, and the coverage reached for the word everyone reaches for: game-changer.^9,14

I'm usually the one applying the brakes when a drug gets that label. Not entirely this time. This is a real advance, the evidence behind it is unusually strong, and it's peer-reviewed in the two journals that matter most. But "biologic-level" is a phrase that hides an asterisk, and the asterisk is the most useful thing in this issue. Let's earn the headline before we believe it.

Hitting the Receptor, By Mouth

Psoriasis is, at its core, an inflammatory feedback loop. A cytokine called interleukin-23 — IL-23 — acts as the master switch for the Th17 immune pathway that drives the scaly, inflamed plaques. Shut down IL-23 signaling and the plaques recede. The injectable biologics do this by being monoclonal antibodies that grab the IL-23 protein itself before it can dock. They work beautifully, but antibodies are large proteins; swallow one and your gut digests it. So they're injected.¹⁰

Icotrokinra takes the other door. It's a small, orally stable peptide that blocks the IL-23 receptor — the docking port on the cell — rather than the circulating cytokine. Same pathway, opposite end of the handshake, and crucially, a molecule engineered to survive the stomach. You take it once a day, on an empty stomach with water, on waking.³ The hard part was never the biology; it was making a targeted peptide that the gut would actually absorb. That's the breakthrough.

This is what separates it from the other pills. Deucravacitinib (Sotyktu) is an oral TYK2 inhibitor — it works one step inside the cell, on a signaling kinase, and is broader in its reach. Apremilast (Otezla) blocks PDE4, broader still and weaker. Icotrokinra brings the narrow, biologic-style precision of IL-23 targeting into oral form, which is exactly why it carries both the strong efficacy of that class and, as we'll see, its notably clean safety signature.¹⁰

Four Phase III Wins, Peer-Reviewed

What makes me comfortable using the word "strong" here isn't the press release — it's that the pivotal data landed in the New England Journal of Medicine and The Lancet, not just a J&J investor deck. The ICONIC program is deep, and it includes the one thing drug companies usually avoid: a head-to-head against a live competitor.

"Biologic-Level" Has an Asterisk

Here's the line that keeps the marketing honest. An independent network meta-analysis pulling together 66 randomized trials placed icotrokinra on par with the injectable IL-23 antibodies — guselkumab, risankizumab — and ahead of every oral. That's the basis for "biologic-level," and it's earned.⁶

But the same analysis put it below the strongest injectables: bimekizumab and brodalumab, which hit the IL-17 pathway, still clear more skin. So "biologic-level" means "as good as the IL-23 shots," not "as good as anything you can inject." If your goal is the absolute maximum — totally clear skin, every patch gone — the ceiling still belongs to a needle.⁶

The other honest framing: the marquee result, beating deucravacitinib, is real and statistically clean — but deucravacitinib is the gentle end of the oral spectrum. Clearing that bar is not the same as matching Skyrizi. The trials didn't pit icotrokinra directly against the top IL-23 injectables, so that comparison lives in indirect modeling, not a head-to-head.⁶

Placebo-Like, and No Boxed Warning

This is where icotrokinra quietly separates from its oral rivals. Through week 16, the overall adverse-event rate was about 49% on the drug and about 49% on placebo — statistically indistinguishable. Serious adverse events were actually lower on the drug, 0.5% versus 1.9%. The common complaints were mild: headache, nausea, cough, fungal infection, fatigue.¹

Crucially, the label carries no boxed warning.³ That matters because the comparison everyone makes — deucravacitinib — sits in the TYK2/JAK structural family, a category that has drawn regulatory caution over cardiovascular and infection signals. By blocking the IL-23 receptor specifically, icotrokinra avoids that baggage. As with any drug that modulates the immune system, there's a sensible precaution around infection, and the label advises screening for tuberculosis before starting. But the headline is a clean profile that looks more like a biologic than a small molecule.

One more thing worth noting for breadth: J&J is testing the same molecule in ulcerative colitis and psoriatic arthritis. Early inflammatory-bowel data are encouraging, and the psoriatic-arthritis trials are running but haven't reported.^6,15 If those land, this becomes a platform, not just a psoriasis pill — but that's a story for a future issue.

Dr. Cole's Verdict